ASCL2 and neoplasm: First, PARCB cell lines derived from the ASCL1 and POU2F3/ASCL2 tumor subtypes were treated with IMT1B, a small molecule inhibitor of mitochondrial RNA polymerase (POLRMT), which blocks mitochondrial DNA transcription thereby downregulating all of the mitochondrially encoded respiratory chain complexes (50).